ALT 0.00% 0.5¢ analytica limited

Ann: Change in directors interest notice - 3, page-24

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 193 Posts.
    lightbulb Created with Sketch. 29
    siren4, I think anything is possible in the sharemarket game, but negotiations are in progress, including for the ASB, and are well within a reasonable time frame.
    My faith is in Corr. A former Dean so good at the theory Pfizer hired him for a senior position. Then, putting theory into practice, he founded his own very successful company.

    The business model of Auven Therapuetics is to buy or take a controlling stake in newish products/businesses, get them ready for commercialization, then do a deal providing a royalty stream. Now he runs Inov8, an investment fund attached to the Tech Park at the Uni of Virgin Islands, which does a similar thing. His integrity is & has to be impeccable. And that's just a summary of his CV.
    He knows what he's doing, and I note his involvement with PeriCoach came after it was obvious sales were floundering. He was there when the decision was made to stop spending resources on sales & focus on the deal.

    Alt has stated majors want our product but requested V3. It is finished although there will be software upgrades, hence the subscription model. A partner might want to alter design aspects.
    There is no competitor that comes remotely close to the quality of PeriCoach let alone have Govt. approvals. We have it for 2 indications.
    A variety of opinions are expressed on this thread, a good thing if they're honest and well stated, and in essence these posts express individual opinions on risk & reward, which is all I'm doing.

    Obviously women would prefer not to have to use it; but to what extent is the 'invasive nature' a deterrent.
    Being male it doesn't sit right for me to guess (thx for posting Jsmama) so I look for logical clues.
    - Designed by a female.
    - Who won an award for it; not her only award.
    - Who now leads product development.
    - Though m'ment and board are male they have Dr as a title so I don't doubt their objectivity.
    - Overwhelming positive feedback from mostly female clinicians.
    - Recommended by mostly female clinicians.
    - Successful use by women to date.
    - Feedback from female bloggers for what it's worth.
    - The market in segments: Severe - they will use it. Moderate, & mild to no problem, guess work; BUT there are good reasons for most adult women to try it, and our partner will be highly skilled at driving acceptance. And several have pointed out we only need a small fraction of multiple markets for big $, which parties currently negotiating also know.
    - It's not a mouse! It's a small medtech device for a part of female anatomy of importance to them.
    It reduces symptoms or risk of. It can reduce need for or risk of surgery. Usage is for a few minutes at a time, and certainly not daily for most.
    Women are adept at discretion. They accept the invasive nature of tampons, probing physicians, dicks (sorry mods, I mean penises). For decades there's been something called something called suppositories - if any don't know what they are ask Tony Abbott. And it just so happens that the vagina is where babies come out of; usually.
    - There are female shareholders; including MM's wife.
    - It will be made in USA by a name brand.
    That's enough for me.
 
watchlist Created with Sketch. Add ALT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.